Walbrook PR, a financial PR and investor relations firm specialising in small cap and AIM listed companies, has been appointed as financial PR advisor on two separate businesses: Motif Bio and Surgical Innovations Group.
Motif Bio is a clinical stage biopharmaceutical company developing antibiotics to fight serious and life-threatening infections. Surgical Innovations designs and manufactures innovative devices for minimally invasive surgery and industrial markets.
Both firms are AIM listed life sciences companies.
Paul McManus, MD and founder of Walbrook PR (pictured), said: “We are delighted to have won the mandates for both Motif Bio and Surgical Innovations – which reinforces our well-established position as a leading PR and IR adviser to smaller growing life sciences’ businesses.”
McManus will handle both accounts. He founded Walbrook PR in 2009 to assist smaller growing companies in raising their profile among investors, analysts, and the media.